Amundi Sells 1,995 Shares of Axon Enterprise, Inc $AXON

Amundi trimmed its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 0.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 434,440 shares of the biotechnology company's stock after selling 1,995 shares during the quarter. Amundi owned 0.53% of Axon Enterprise worth $243,551,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AXON. Wellington Grp LLC grew its position in shares of Axon Enterprise by 145.4% in the 2nd quarter. Wellington Grp LLC now owns 1,411 shares of the biotechnology company's stock worth $791,000 after buying an additional 836 shares during the last quarter. Carlson Financial Inc. boosted its holdings in Axon Enterprise by 2.7% in the second quarter. Carlson Financial Inc. now owns 16,039 shares of the biotechnology company's stock valued at $8,992,000 after acquiring an additional 415 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Axon Enterprise by 55,955.7% in the second quarter. California State Teachers Retirement System now owns 64,781,849 shares of the biotechnology company's stock valued at $36,317,352,000 after acquiring an additional 64,666,282 shares in the last quarter. Washington Trust Advisors Inc. increased its position in Axon Enterprise by 1,300.0% during the 2nd quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 65 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new position in Axon Enterprise during the 2nd quarter valued at $236,000. Institutional investors own 79.08% of the company's stock.

Insider Activity

In related news, CEO Patrick Smith sold 10,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $643.79, for a total transaction of $6,437,900.00. Following the sale, the chief executive officer directly owned 3,040,997 shares of the company's stock, valued at $1,957,763,458.63. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the sale, the president owned 296,974 shares of the company's stock, valued at $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 56,380 shares of company stock valued at $32,582,366 over the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on AXON shares. Citizens Jmp reaffirmed a "market outperform" rating and issued a $700.00 target price on shares of Axon Enterprise in a research report on Thursday, June 25th. Needham & Company LLC reiterated a "buy" rating on shares of Axon Enterprise in a research report on Wednesday, September 2nd. The Goldman Sachs Group reiterated a "buy" rating and set a $715.00 price target on shares of Axon Enterprise in a research report on Thursday, August 6th. TD Cowen reissued a "buy" rating on shares of Axon Enterprise in a research note on Wednesday, July 22nd. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and an average price target of $721.57.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $515.67 on Tuesday. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $792.16. The company has a market capitalization of $41.89 billion, a price-to-earnings ratio of 213.97, a price-to-earnings-growth ratio of 10.06 and a beta of 1.40. The business's fifty day simple moving average is $569.57 and its two-hundred day simple moving average is $487.23. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company's revenue was up 35.3% on a year-over-year basis. During the same period last year, the company earned $2.12 earnings per share. As a group, equities analysts predict that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.